

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® / Pen to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (lebrizumab-ibk) Syringes / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in RED) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

Yellow shade signifies a new product being added as a new to market Non-Preferred product OR current coverage is being clarified		
Orange shade signifies a significant change to the drug, category, or a clinical recommendation		
Pink Shade signifies an Off-Cycle PDL move from Preferred to Non-Preferred or vice versa		
Green shade signifies a Brand / Generic switch within the same category		
Peach shade signifies categories that will be open for discussion even though there are no recommendations in that category		
Purple shade signifies a product either no longer covered (rebatable) or no longer available from the manufacturer		
ALZHEIMER'S AGENTS		
Preferred		Non-Preferred
donepezil 5mg, 10mg tablet / ODT (generic for Aricept® / ODT)	Adlarity® Patch	
Exelon® Patch	Aduhelm® Vial - Clinical criteria apply	
memantine tablet / titration pack (generic for Namenda®)	Aricept® Tablet	
rivastigmine capsule (generic for Exelon®)	donepezil 23mg tablet (generic for Aricept®)	
	galantamine ER capsule / solution / tablet (generic for Razadyne® / ER)	
	Kisunla™ (donanemab-azbt) Vial	
	Leqembi® Vial / Autoinjector - Clinical criteria apply	
	memantine ER capsule / solution (generic for Namenda® XR / Solution)	
	Memantine HCL- Donepezil HDL ER capsule (generic for NAMZARIC®)	
	Namenda® Titration Pack / XR Capsule / XR Titration Pack	
	Namzaric® Capsule / Titration Pack	
	rivastigmine patch (generic for Exelon®)	
	Zunveyr® tablet	
ANALGESICS		
OPIOID ANALGESICS		
Long Acting Opioids		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all drugs in this class		
Preferred		Non-Preferred
Butrans® Patch	Belbuca® (Buccal) Film	
fentanyl patch 12mcg / 25mcg / 50mcg / 75mcg / 100mcg (generic for Duragesic®)	buprenorphine patch (generic for Butrans®)	
methadone concentrate / diskets / intensol / tablets / solution	Conzip® Capsule	
morphine sulfate ER tablet (generic for MS Contin®)	fentanyl patch (37.5 / 62.5 / 87.5mcg dosages) (generic for Duragesic®)	
OxyContin® Tablet	hydrocodone ER capsule (generic for Zohydro® ER)	
	hydrocodone ER tablet (generic for Hysingla® ER)	
	hydromorphone ER tablet (generic for Exalgo®)	
	Hysingla™ ER Tablet	
	Methadose® Oral Concentrate / Tablet	
	morphine sulfate ER capsule (generic for Aviza®, Kadian®)	
	MS Contin® Tablet	
	oxycodone ER tablet (generic for OxyContin®)	
	oxymorphone ER tablet	
	tramadol ER capsule (generic for Conzip®)	
	tramadol ER tablet (Ultram ER®, Ryzolt®)	
Short Acting Schedule II Opioids		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all drugs in this class		
Preferred		Non-Preferred
Endocet® Tablet (branded generic for Percocet®)	codeine sulfate tablet	
hydrocodone-acetaminophen solution / tablet (generic for Hycet®, Lorcet®, Lortab®, Norco®, Vicodin®)	Dilaudid® Liquid / Tablet	
hydromorphone tablet (generic for Dilaudid®)	hydrocodone-acetaminophen Solution (generic for Zolvit)	
morphine solution / tablet (generic for MSIR®)	hydrocodone-ibuprofen tablet (generic for Ibudone®, Reprexain®, Vicoprofen®)	
oxycodone solution / tablet (generic for Roxicodone®)	hydromorphone solution / suppository (generic for Dilaudid®)	
oxycodone-acetaminophen capsules (generic for Tylox®)	levorphanol tablet (generic for Levo-Dromoran®)	
oxycodone-acetaminophen tablets (generic for Percocet®)	meperidine solution / tablet (generic for Demerol®)	
	morphine oral syringe	
	morphine suppositories (generic for Roxanol®)	
	Nalocet® Tablet	
	oxycodone capsule (generic for OxyIR®)	
	oxycodone concentrated solution (generic for Roxicodone® Intensol)	
	oxycodone-acetaminophen solution	
	oxymorphone tablet (generic for Opana®)	
	Percocet® Tablet	
	Prolate® Tablet / Solution	
	Roxicodone® Tablet	
	Roxybond® Tablet	
Short Acting Schedule III – IV Opioids / Analgesic Combinations		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all drugs in this class		
Preferred		Non-Preferred
codeine-acetaminophen solution / tablet (generic for Tylenol with Codeine®)	Ascomp® Capsule (branded generic for Fiorinal with Codeine®)	
tramadol tablet 50 mg (generic for Ultram®)	bupital compound with codeine capsule (generic for Fiorinal with Codeine®)	
tramadol-acetaminophen tablet (generic for Ultracet®)	bupitalbital-caffeine-APAP with codeine tablet (generic for Fioricet with Codeine®)	
	butorphanol spray (generic for Stadol®)	
	dihydrocodeine-acetaminophen-caffeine tablet (generic for Panlor SS®)	
	Fioricet with Codeine® Capsule	
	pentazocine-naloxone tablet (generic for Talwin NX®)	
	tramadol solution (generic for Qdolo™)	
	tramadol tablet (25 mg, 75 mg, 100 mg)	
NON-OPIOID ANALGESICS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Journavx™ Tablet Quantity limit of a 14 day supply		

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Antithrombotics category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill / FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (lebrizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Vismar® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

NSAIDS		
Preferred		Non-Preferred
celecoxib capsule (generic for Celebrex®)	Arthrotec® Tablet	
diclofenac sodium tablet (generic for Voltaren®)	Celebrex® Capsule	
ibuprofen suspension / tablet (generic for Motrin®)	Coxanta™ Capsule	
indomethacin capsule (generic for Indocin®)	Dainpro® Caplet	
ketorolac tablet (generic for Toradol®)	diclofenac potassium capsule (generic for Zipsor®)	
meloxicam tablet (generic for Mobic®)	diclofenac potassium tablet (generic for Cataflam®)	
naproxen EC / DR tablet (generic for Naprosyn® EC)	diclofenac sodium ER tablet (generic for Voltaren® XR)	
naproxen sodium tablet (generic for Anaprox®)	diclofenac sodium-misoprostol tablet (generic for Arthrotec®)	
naproxen tablet (generic for Naprosyn®)	diflunisal tablet (generic for Dolobid®)	
sulindac tablet (generic for Clinoril®)	Dolobid tablet	
	etodolac capsule / tablet / ER tablet (generic for Lodine® / XL)	
	Feldene® Capsule	
	fenoprofen capsule/ tablet (generic for Nalfon®)	
	flurbiprofen tablet (generic for Ansaid®)	
	ibuprofen / famotidine tablet (generic for Duoasis®) - T/F of only celecoxib required	
	indomethacin ER capsule (generic for Indocin SR®)	
	indomethacin suppository	
	ketoprofen capsule (generic for Orudis®)	
	ketoprofen ER capsule (generic for Oruvail®)	
	Kiprofen™ (ketoprofen) Capsule (branded generic for Orudis®)	
	Lofena™ Tablet	
	Lurbiro™ Tablet	
	meclizemate capsule (generic for Meclomen®)	
	mefenamic acid capsule (generic for Ponstel®)	
	meloxicam capsule (generic for Vivlodex®)	
	rabumetone tablet (generic for Relafen®)	
	Nalfon® Capsule / Tablet	
	Naprelan® Tablet	
	Naprosyn® Suspension	
	naproxen sodium ER tablet (generic for Naprelan®)	
	naproxen suspension (generic for Naprosyn®)	
	naproxen-esomeprazole tablet (generic for Vimovo®) - T/F of only celecoxib required	
	oxaprozin tablet (generic for DayPro®)	
	piroxicam capsule (generic for Feldene®)	
	Relafen™ DS Tablet	
	Tolectin® (tolmetin) Tablet	
	tolmetin tablet / capsule (generic for Tolectin® / DS)	
	Vimovo® Tablet - T/F of only celecoxib required	
	Vyscxa® Suspension	
NEUROPATHIC PAIN		
Preferred		Non-Preferred
duloxetine capsule (generic for Cymbalta®)	Cymbalta® Capsule	
gabapentin capsule / solution / tablet (generic for Neurontin®)	DermacinRx™ Lidocan Patch - Clinical criteria apply	
lidocaine patch (generic for Lidoderm®) - Clinical criteria apply	Drizalma™ Sprinkle	
pregabalin capsule / solution (generic for Lyrica®)	duloxetine capsule (generic for Irenka®)	
	gabapentin ER tablet (generic for Gralise®)	
	Gabrone™ Tablet	
	Gralise® Tablet	
	Horizant® Tablet	
	Lidocan™ Patch - Clinical criteria apply	
	Lidoderm® Patch - Clinical criteria apply	
	Lyrica® Capsule / Solution / CR Tablet	
	Neurontin® Capsule / Solution / Tablet	
	pregabalin ER tablet (generic for Lyrica® CR)	
	Quenza® Kit	
	Savella® Tablet / Titration Pack	
	Tridacaine™ Patch	
	ZTLido™ Patch - Clinical criteria apply	
ANTICONVULSANTS		
CARBAMAZEPINE DERIVATIVES		
Plans may not apply additional utilization management or prior authorization criteria to this category. Patients with a diagnosis of seizure disorder are exempt from T/F criteria and may use any carbamazepine product.		
Preferred		Non-Preferred
carbamazepine tablet / suspension / chewable tablet / XR tablet (generic for Tegretol® / XR)	Aptiom® Tablet	
Equetro® Capsule	carbamazepine ER capsule (generic for Carbatrol®)	
eslicarbazepine acetate Tablet (generic for Aptiom®)	Carbatrol® Capsule	
oxcarbazepine suspension / tablet (generic for Trileptal®)	Epitol® Tablet	
Oxtellar® XR Tablet	Oxcarbazepine ER (generic for Oxtellar® XR)	
Tegretol® Suspension / Tablet / XR Tablet	Trileptal® Tablet	
Trileptal® Suspension		
FIRST GENERATION		
Patients with a diagnosis of seizure disorder are exempt from T/F criteria and may use any first generation product.		
Preferred		Non-Preferred
Celontin® Kapsal	Depakote® ER Tablet / Sprinkle Capsule	
Dilantin® Capsule / Infatab / Suspension	Depakote® Tablet	
divalproex sprinkle capsule / ER tablet / tablet (generic for Depakote® / ER / Sprinkle)	felbamate tablet (generic for Felbatol®)	
ethosuximide capsule / solution (generic for Zarontin®)	methsuximide capsule (generic for Celontin®)	
felbamate suspension (generic for Felbatol®)	Sezaby® Vial	
Felbatol® Suspension / Tablet	Zarontin® Capsule / Solution	
phenobarbital tablet / elixir / solution		
Phenytek® Capsule		
phenytoin chewable / extended capsules / infatab / suspension (generic for Dilantin®)		
phenytoin extended capsules (generic for Phenytek®)		
primidone Tablet (generic for Mysoline®)		
valproic acid capsule / solution (generic for Depakene®)		

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill®/PenPach® Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (lebrizumab-ibk) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Banagla® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

SECOND GENERATION		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Patients with a diagnosis of seizure disorder are exempt from T/F criteria and may use any second generation product.		
Preferred		Non-Preferred
Briviact® Tablet / Solution	Banzel® Suspension	
clobazam suspension / tablet (generic for Onfi®)	Banzel® Tablet	
clonazepam tablet (generic for Klonopin®)	Brivaracetam Tablet (generic for Briviact®)	
Diacomit® Capsule / Powder Pack	clonazepam ODT (generic for Klonopin® Wafer)	
diazepam rectal / system (generic for Diastat® Accudial / Pedi System)	Elespia™ XR Tablet	
Eprontia™ Solution	Epidiolex® Solution - Clinical criteria apply	
Fintepia® Solution	Gabarone™ Tablet	
Fycompa® Tablet / Suspension	Keppra® Tablet / Solution / XR Tablet	
gabapentin capsule / solution / tablet (generic for Neurontin®)	Klonopin® Tablet	
lacosamide tablet (generic for Vimpat®)	lacosamide solution (generic for Vimpat®)	
lamotrigine chewable / tablet / ODT (generic for Lamictal®)	Lamictal® Chewable / ODT / ODT Starter Kit / Starter Kit / Tablet / XR / XR Starter Kit	
lamotrigine ER tablet (generic for Lamictal® XR)	lamotrigine ODT dose pack/ tablet dose pack (generic for Lamictal®)	
levetiracetam tablet / ER tablet / solution (generic for Keppra® / XR)	Levetiracetam tablet (generic for Spritam®)	
Nayzilam® Nasal Spray	Libervant™ (diazepam) Buccal Film	
Quexy® XR Capsule	Lyricea® Capsule / Solution	
Rowcepra™ Tablet	Motopoly XR™ (lacosamide extended release) Capsule	
rufinamide suspension (generic for Banzel®)	Neurontin® Capsule / Solution / Tablet	
rufinamide tablet (generic for Banzel®)	Onfi® Suspension / Tablet	
Sabril® Tablet / Powder Packet	perampanel Tablet / Suspension (generic for Fycompa®)	
Subventie® Tablet / Tab Start Kit	Spritam® Tablet	
tiagabine tablet (generic for Gabitril®)	Sympazan® Film	
topiramate sprinkle capsule / tablet (generic for Topamax®)	Topamax® Sprinkle Capsule / Tablet	
Valtoco® Nasal Spray	topiramate ER capsule (generic for Trokendi XR®) - T/F of Trokendi® XR Capsule required for coverage	
vigabatrin Powder Packet (generic for Sabril®)	topiramate ER sprinkle capsule (generic for Quexy®)	
Xcopri® Tablet / Titration Pack	Topiramate Solution	
zonisamide capsule (generic for Zonegran®)	Trokendi® XR Capsule	
	vigabatrin tablet (generic for Sabril®)	
	Vigadrone® Powder Packet / Tablet	
	Vigafyde™ Solution	
	Vigpoder™ Powder Packet	
	Vimpat® Solution / Starter Kit / Tablet	
	Zonisade™ Oral Suspension	
	Zulmy® Oral Suspension	
ANTI-INFECTIVES - SYSTEMIC		
ANTIBIOTICS		
Penicillins, Cephalosporins and Related		
Preferred		Non-Preferred
amoxicillin capsule / chewable / suspension / tablet (generic for Amoxil®, Trimox®)	amoxicillin-clavulanate chewable tablet (generic for Augmentin®)	
amoxicillin-clavulanate suspension / tablet (generic for Augmentin®)	amoxicillin-clavulanate XR tablet (generic for Augmentin® / XR)	
ampicillin capsule / injection / vial	Augmentin® Suspension / ES-600 / XR Tablet	
ampicillin-sulbactam injection / vial	cefaclor capsule / suspension / ER tablet (generic for Cefclor® / CD)	
Bicillin® C-R injection	cefadroxil tablet (generic for Duricef®)	
cefadroxil capsule / suspension (generic for Duricef®)	ceftixime Tablet (generic for Suprax®)	
cefdinir capsule / suspension (generic for Omnicef®)	ceftixime suspension (generic for Suprax®) T/F of preferred agents not required for children < 12 years of age	
cefixime capsule (generic for Suprax®)	cefepodoxime suspension / tablet (generic for Vantin®)	
cefprozil suspension / tablet (generic for Cefzil®)	cephalexin tablet (generic for Keflex®)	
cefuroxime tablet (generic for Cefin®)	piperacillin - tazobactam IV piggy back	
cephalexin capsule / suspension (generic for Keflex®)		
dicloxacillin capsule		
nafcillin injection / vial		
oxacillin injection / vial		
penicillin G injection / vial		
penicillin V suspension / tablet		
Pfizerpen® injection / vial		
piperacillin - tazobactam injection / vial		
Unasyn® injection / vial		
Zosyn® injection / vial		
Lincosamides and Oxazolidinones		
Preferred		Non-Preferred
clindamycin capsules / solution (generic for Cleocin®)	Cleocin Pediatric Solution	
linezolid suspension (oral) / tablet (generic for Zyvox®)	Cleocin® Capsules / Vial	
	clindamycin injection (generic for Cleocin®)	
	Lincocin® Vial	
	lincomycin vial (generic for Lincocin®)	
	linezolid IV solution (generic for Zyvox®)	
	Sivextro® Tablet / Vial	
	Zyvox® Tablet / IV Solution / Suspension	
Macrolides and Ketolides		
Preferred		Non-Preferred
azithromycin powder packet / suspension / tablet (generic for Zithromax®)	clarithromycin ER tablet (generic for Biaxin XL®)	
clarithromycin suspension / tablet (generic for Biaxin®)	Eryped® 200/400 Suspension	
E.E.S.® Filmtab / Suspension	Ery-Tab® Tablet	
Erythrocin® Filmtab	Zithromax® Powder Packet / Suspension / Tablet / Tri-Pak / Z-Pak	
erythromycin ES 200 mg and 400 mg suspension (generic for E.E.S.® Suspension, Eryped®)		
erythromycin EC capsule (generic for Eryc®)		
erythromycin filmtab		
erythromycin ES tablet (generic for E.E.S.® Filmtab)		
Nitroimidazoles (Gastrointestinal Antibiotics)		
Preferred		Non-Preferred
metronidazole tablet (generic for Flagyl®)	Aemcolo® DR Tablet	
vancomycin capsule (generic for Vancocin®)	Difcid® Suspension / Tablet - T/F of only vancomycin is required for treatment of Clostridium difficile	
vancomycin oral solution (generic for Firvang®)	fidaxomicin Tablet (generic for Difcid®)- T/F of only vancomycin is required for treatment of Clostridium difficile	
	Firvang® Solution	
	Flagyl® Capsule	
	Likmez™ Suspension	
	metronidazole 125 mc tablet (generic for Flagyl®)	
	metronidazole capsule (generic for Flagyl®)	
	neomycin tablet (generic for Mycifradin®)	
	nitazoxanide tablet (generic for Alinia® Tablet)	
	Solosec™ Granules	
	timidazole tablet (generic for Tmdamax®)	
	Vancocin® Capsule	
	Vowst™ Capsule - Clinical criteria apply	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill / Pen to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (elbrikimab-ibk) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

Quinolones	
Preferred	Non-Preferred
Cipro [®] Suspension	Baxdela [™] Tablet
ciprofloxacin tablet (generic for Cipro [®])	Cipro [®] Tablet
levofloxacin tablet (generic for Levaquin [®])	ciprofloxacin suspension (generic for Cipro [®])
moxifloxacin tablet (generic for Avelox [®])	levofloxacin solution (generic for Levaquin [®])
	ofloxacin tablet (generic for Floxin [®])
Tetracycline Derivatives	
Preferred	Non-Preferred
doxycycline hyclate capsule / tablet (generic for Vibramycin [®] , Vibra-Tab [®])	demeclocycline tablet (generic for Declomycin [®])
doxycycline monohydrate 50mg, 100mg capsule (generic for Monodox [®])	Doryx [®] DR / MPC Tablet
minocycline 50mg, 75mg, 100mg capsule (generic for Minocin [®])	doxycycline hyclate DR tablet (generic for Doryx [®] DR)
	doxycycline monohydrate 40mg IR-DR capsule (generic for Oracea [®])
	doxycycline monohydrate 50mg, 75mg, 100mg, 150mg tablet
	doxycycline monohydrate 75mg, 150mg capsule (generic for Monodox [®] , Adoxa [®])
	doxycycline suspension (generic for Vibramycin [®]) - T/F of preferred agents not required for patients < 12 years of age
	Lympapak [™] Tablet
	minocycline 50mg, 75mg, 100mg tablet
	minocycline ER tablet (generic for Solodyn [®] ER) Clinical justification and failure of doxycycline and minocycline required. Limited to a 12 week supply.
	Morgidox [®] Capsule / Kit
	Nuzyna [™] Tablet
	Oracea [®] capsule
	tetracycline capsule (generic for Sumycin [®])
	tetracycline tablet (generic for Sumycin [®] / Parmycin [®])
Antifungals	
Preferred	Non-Preferred
clotrimazole troche / lozenge (generic for Mycelex [®] Troche)	Brexafemme [®] Tablet
fluconazole suspension / tablet (generic for Diflucan [®])	Cresemba [®] Capsule
griseofulvin suspension (generic for Grifulvin V [®])	Diflucan [®] Suspension / Tablet
griseofulvin ultra tablet (generic for Gris-Peg [®])	flucytosine capsule (generic for Ancobon [®])
mycstatin suspension (generic for Nilstat [®])	griseofulvin micro tablets (generic for Grifulvin V [®])
mycstatin tablet (generic for Mycostatin [®])	itraconazole capsule / solution (generic for Sporanox [®])
terbinafine tablet (generic for Lamisil [®])	ketoconazole tablet (generic for Nizoral [®])
	Noxafil [®] Suspension / Tablet / DR Suspension Packet
	Oravir [®] Buccal Tablet
	posaconazole tablet / suspension (generic for Noxafil [®])
	Sporanox [®] Capsule / Solution
	Tolsura [™] Capsule
	Vfend [®] Suspension / Tablet
	Vivjoa [®] Capsule - Clinical criteria apply
	voriconazole suspension / tablet (generic for Vfend [®])
Antivirals (General)	
Preferred	Non-Preferred
Paxlovid [™] Tablet dose Pack	
Lagevrio [™] Capsule	
Antivirals (Hepatitis B Agents)	
Preferred	Non-Preferred
entecavir tablet (generic for Baraclude [®])	adefovir tablet (generic for Hepsera [®])
lamivudine HBV tablet (generic for Epivir [®] HBV)	Baraclude [®] Solution / Tablet
tenofovir disoproxil fumarate tablet (generic for Viread [®])	Vemlidy [®] Tablet
Viread [®] Powder / Tablet	
Antivirals (Hepatitis C Agents)	
Preferred	Non-Preferred
Pegasys [®] Syringe / Vial	
ribavirin capsule / tablet (generic for Copegus [®] , Rebetasol [®])	
Clinical criteria apply to all drugs listed below	
Prior Approval Not Required for Mavyret [®] Tablet / Pellet Pack and sofosbuvir-velpatasvir tablet (generic for Epclusa [®])	
All genotypes without cirrhosis	
Mavyret [®] Tablet (8 weeks of therapy)	Epclusa [®] Pellet Pack/Tablet
Mavyret [®] Pellet Pack	Harvoni [®] Pellet Pack / Tablet
sofosbuvir-velpatasvir tablet (generic for Epclusa [®])	ledipasvir-sofosbuvir tablet (generic for Harvoni [®])
	Sovaldi [®] Pellet Pack / Tablet
	Zepatier [®] Tablet
All genotypes with compensated cirrhosis (Child Pugh-A)	
Mavyret [®] Tablet (Up to 12 weeks of therapy)	
Mavyret [®] Pellet Pack	
sofosbuvir-velpatasvir tablet (generic for Epclusa [®])	
All genotypes previously treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.	
Vosevi [™] Tablet	
All genotypes with decompensated cirrhosis	
sofosbuvir-velpatasvir tablet (generic for Epclusa [®])	
Antivirals (Herpes Treatments)	
Preferred	Non-Preferred
acyclovir capsule / tablet / suspension (generic for Zovirax [®])	Valtrex [®] Caplet
famciclovir tablet (generic for Famvir [®])	
valacyclovir tablet (generic for Valtrex [®])	
Antivirals (Influenza)	
Preferred	Non-Preferred
oseltamivir phosphate capsule / suspension (generic for Tamiflu [®])	amantadine tablet (generic for Symmetrel [®])
rimantadine tablet (generic for Flumadine [®])	Flumadine [®] Tablet
	Relenza [®] Diskhaler
	Tamiflu [®] Capsule / Suspension
	Xofluza [™] Tablet - T/F of only one preferred drug required

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill®/FlexPen® Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (ibekizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Vismar® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED.** For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://medicaid.ncdhhs.gov/> then click on the **Pharmacy Benefit Administrator** tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

INJECTABLE ANTIPSYCHOTICS		
Injectable Long Acting		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Ablify Asimtufil® Syringe Kit		
Ablify Maintena® Syringe / Vial		
Aristada® / Initio™ Syringe		
Erzofri® (paliperidone palmitate) extended-release injectable suspension		
fluphenazine decanoate vial (generic for Prolixin decanoate®)		
Haldol® decanoate Ampule		
haloperidol decanoate ampule / vial (generic for Haldol decanoate®)		
Invenga® Hafyera Prefilled Syringe Kit		
Invenga® Sustenna Prefilled Syringe		
Invenga® Trinzta Syringe		
Perseris® Syringe		
Risperdal® Consta Vial		
risperidone ER vial (generic for Risperdal® Consta)		
Rykindo® Vial / Vial Kit		
Uzedy™ Syringe Kit		
Zyprexa® Relprevv™ Vial Kit		
ATYPICAL ANTIPSYCHOTICS		
Oral / Transdermal		
Plans may not apply additional utilization management or prior authorization criteria to this category		
T/F of only one preferred drug required		
Preferred		Non-Preferred
aripiprazole Tablet / Solution (generic for Abilify®)	Ablify® Tablet / Abilify® MyCite® Tablet	
asenapine SL tablet (generic for Saphris® SL)	aripiprazole ODT (generic for Abilify® Discmelt®)	
clozapine tablet (generic for Clozaril®)	Caplyta® Capsule	
lurasidone tablet (generic for Latuda®)	clozapine ODT (generic for FazaClo®)	
olanzapine ODT / tablet (generic for Zyprexa®)	Clozaril® Tablet	
paliperidone ER tablet (generic for Invenga®)	Cobenly	
quetiapine tablet / ER tablet (generic for Seroquel® / XR)	Cobenly Starter Pack	
risperidone ODT / solution / tablet (generic for Risperdal®)	Fanapt® Tablet / Titration Pack	
Vraylar® Capsule	Geodon® Capsule	
ziprasidone capsule (generic for Geodon®)	Invenga® Tablet	
	Latuda® Tablet	
	Lybalvi™ Tablet	
	Nuplazid® Tablet / Capsule	
	olanzapine-fluoxetine capsule (generic for Symbyax®)	
	Opipza™ (Aripiprazole) Oral Film	
	Rexulti® Tablet / 7-Day Pack / 14-Day Pack	
	Risperdal® Solution / Tablet	
	Saphris® SL Tablet	
	Secundo® Patch	
	Seroquel® Tablet / XR Tablet / XR Sample Kit	
	Versacloz® Suspension	
	Zyprexa® Tablet / Zydys® Tablet	
CARDIOVASCULAR		
ACE INHIBITORS		
Preferred		Non-Preferred
benazepril tablet (generic for Lotensin®)	Accupril® Tablet	
enalapril tablet (generic for Vasotec®)	Altace® Capsule	
lisinopril tablet (generic for Prinivil® and Zestril®)	captopril tablet (generic for Capoten®)	
ramipril capsule (generic for Altace®)	enalapril solution (generic for Epaned®) - T/F of preferred agents not required for children < 12 years of age	
	Epaned® Solution - T/F of preferred agents not required for children < 12 years of age	
	fosinopril tablet (generic for Monopril®)	
	Lotensin® Tablet	
	moexipril tablet (generic for Univase®)	
	perindopril tablet (generic for Aceon®)	
	Qbrelis® Solution - T/F of preferred agents not required for children < 12 years of age	
	quinapril tablet (generic for Accupril®)	
	trandolapril tablet (generic for Mavik®)	
	Zestril® Tablet	
ACE INHIBITOR / CALCIUM CHANNEL BLOCKER COMBINATIONS		
Preferred		Non-Preferred
amlodipine-benazepril capsule (generic for Lotrel®)	Lotrel® Capsule	
	trandolapril-verapamil ER tablet (generic for Tarka®)	
ACE INHIBITOR / DIURETIC COMBINATIONS		
Preferred		Non-Preferred
enalapril-HCTZ tablet (generic for Vasercite®)	Accuretic® Tablet	
lisinopril-HCTZ tablet (generic for Prinzide®, Zestoretic®)	benazepril-HCTZ tablet (generic for Lotensin® HCT)	
	captopril-HCTZ tablet (generic for Capozide®)	
	fosinopril-HCTZ tablet (generic for Monopril® HCT)	
	Lotensin® HCT Tablet	
	quinapril-HCTZ tablet (generic for Accuretic®, Quinaretic®)	
	Vasercite® Tablet	
	Zestoretic® Tablet	
ANGIOTENSIN II RECEPTOR BLOCKERS		
Preferred		Non-Preferred
irbesartan tablet (generic for Avapro®)	Arbli™ Suspension	
losartan tablet (generic for Cozaar®)	Atacand® Tablet	
olmesartan tablet (generic for Benicar®)	Avapro® Tablet	
valsartan tablet (generic for Diovan®)	Benicar® Tablet	
	candesartan tablet (generic for Atacand®)	
	Cozaar® Tablet	
	Diovan® Tablet	
	Edarbi® Tablet	
	eprosartan tablet (generic for Teveten®)	
	Micardis® Tablet	
	telmisartan tablet (generic for Micardis®)	
	valsartan oral solution	
ANGIOTENSIN II RECEPTOR BLOCKER COMBINATIONS		
Preferred		Non-Preferred
amlodipine-olmesartan tablet (generic for Azor®)	Azor® Tablet	
amlodipine-valsartan tablet (generic for Exforge®)	Exforge® Tablet / HCT Tablet	
olmesartan-amlodipine-HCTZ tablet (generic for Tribenzor®)	telmisartan-amlodipine tablet (generic for Twynsta®)	
	Tribenzor® Tablet	
	amlodipine-valsartan-HCTZ tablet (generic for Exforge® HCT)	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® (PanPen®) Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (lebrizumab-ibk) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Vismar® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

ANGIOTENSIN II RECEPTOR BLOCKER DIURETIC COMBINATIONS		
Preferred		Non-Preferred
irbesartan-HCTZ tablet (generic for Avalide®)	Atacand® HCT Tablet	
losartan-HCTZ tablet (generic for Hyzaar®)	Avalide® Tablet	
olmesartan-HCTZ tablet (generic for Benicar® HCT)	Benicar® HCT Tablet	
valsartan-HCTZ tablet (generic for Diovan® HCT)	candesartan-HCTZ tablet (generic for Atacand® HCT)	
	Diovan® HCT Tablet	
	Edarbyclor® Tablet	
	Hyzaar® Tablet	
	Micardis® HCT Tablet	
	telmisartan-HCTZ tablet (generic for Micardis® HCT)	
ANGIOTENSIN II RECEPTOR / NEPRILYSIN BLOCKER COMBINATIONS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
sacubitril and valsartan tablet (generic for Entresto®)	Entresto® (sacubitril / valsartan) Sprinkle Pellet- T/F of preferred agents not required for children < 12 years of age	
	Entresto® Tablet	
ANTHANGINAL & ANTI-ISCHEMIC		
Preferred		Non-Preferred
ranolazine ER tablet (generic for Ranexa® Tablet)		
ANTI-ARRHYTHMICS		
Preferred		Non-Preferred
amiodarone tablet (generic for Cordarone®)	Multaq® Tablet	
disopyramide capsule (generic for Norpace®)	Norpace® Capsule / CR Capsule	
dofetilide capsule (generic for Tikosyn®)	Pacerone® Tablet	
flecainide tablet (generic for Tambocor®)	quinidine gluconate ER tablet (generic for Quinaglute DuraTabs®)	
mexiletine capsule (generic for Mexitil®)	Tikosyn® Capsule	
propafenone tablet (generic for Rythmol®)		
propafenone SR capsule (generic for Rythmol SR®)		
quinidine sulfate tablet (generic for Quinidex® Tablet)		
BETA BLOCKERS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
atenolol tablet (generic for Tenormin®)	acebutolol capsule (generic for Sectral®)	
bisoprolol tablet (generic for Zebeta®)	Betapace® Tablet / AF Tablet	
carvedilol tablet (generic for Coreg®)	betaxolol tablet (generic for Kerlone®)	
Hemangeol® Solution	Bystolic® Tablet	
labetalol tablet (generic for Trandate®)	carvedilol ER capsule (generic for Coreg® CR Capsule)	
metoprolol succinate XL tablet (generic for Toprol XL®)	Inderal® LA Capsule / XL Capsule	
metoprolol tartrate tablet (generic for Lopressor®)	Imopran® XL Capsule	
nadolol tablet (generic for Corgard®)	Kappargo™ Sprinkle - T/F of preferred agents not required for children < 12 years of age	
nebivolol tablet (generic for Bystolic®)	Lopressor® Tablet / Solution	
propranolol solution / tablet / ER capsule (generic for Inderal®)	pindolol tablet (generic for Visken®)	
sotalol tablet / AF tablet (generic for Betapace® / AF, Sorine®)	Sotylize® Solution	
	Tenormin® Tablet	
	timolol tablet (generic for Blocadren®)	
	Toprol XL® Tablet	
BETA BLOCKER DIURETIC COMBINATIONS		
Preferred		Non-Preferred
atenolol-chlorthalidone tablet (generic for Tenoretic®)	metoprolol-HCTZ tablet (generic for Lopressor® HCT)	
bisoprolol-HCTZ tablet (generic for Ziac®)	propranolol-HCTZ tablet (generic for Inderide®)	
	Tenoretic® Tablet	
BILE ACID SEQUESTRANTS		
Preferred		Non-Preferred
cholestyramine packet / powder / light packet / light powder (generic for Questran® / Questran® Light)	colexsevelam packet / tablet (generic for Welchol®)	
colestipol tablet (generic for Colestid® Tablet)	Colestid® Granules / Tablet	
	colestipol granules (generic for Colestid®)	
	Prevaitte® Packet / Powder	
	Questran® Light Powder / Packet / Powder	
	Welchol® Packet / Tablet	
CARDIOVASCULAR, OTHER		
Preferred		Non-Preferred
Camzyos® Capsule - Clinical criteria apply	Lodoco®	
CHOLESTEROL LOWERING AGENTS		
Preferred		Non-Preferred
atorvastatin tablet (generic for Lipitor®)	Altoprev® Tablet	
ezetimibe (generic for Zetia®)	amlodipine-atorvastatin tablet (generic for Caduet®)	
lovastatin tablet (generic for Mevacor®)	Atorvaliq® Suspension	
pravastatin tablet (generic for Pravachol®)	Caduet® Tablet	
rosuvastatin tablet (generic for Crestor®)	Crestor®	
simvastatin tablet (generic for Zocor®)	Ezallor™ Capsule	
	ezetimibe-simvastatin (generic for Vytorin®)	
	fluvastatin capsule / ER tablet (generic for Lescol® / XL)	
	Juxtapid® Capsule - Clinical criteria apply	
	Lescol® XL Tablet	
	Lipitor® Tablet	
	Livalo® Tablet - T/F of preferred agents not required with concomitant antiretroviral therapy in patients diagnosed with HIV	
	Nexletol® Tablet - Clinical criteria apply	
	Nexlizet® Tablet - Clinical criteria apply	
	pitavastatin tablet (generic for Livalo®) - T/F of preferred agents not required with concomitant antiretroviral therapy in patients diagnosed with HIV	
	Vytorin® Tablet	
	Zetia® Tablet	
	Zocor® Tablet	
	Zypitamaz™ Tablet	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (elbrikizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to **Non-Preferred** status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

CORONARY VASODILATORS	
Preferred	Non-Preferred
isosorbide dinitrate tablet (generic for Isordil® Titradose®, IsoDitrate®, et.al.)	Gonitro® Sublingual Powder
isosorbide mononitrate tablet / ER tablet (generic for Ismo®, Monoket®, Imdur®)	Nitro-Bid® Ointment
nitroglycerin patch / spray / SL tablet (generic for Nitro-Dur®, Minitran®, Nitrostat®, et. al)	Nitro-Dur® Patch
Nitrostat® SL Tablet	nitroglycerin ointment (generic for Nitro-Bid®)
	Nitroglual® Spray
	Verquvo® Tablet
DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Preferred	Non-Preferred
amlodipine tablet (generic for Norvasc®)	felodipine ER tablet (generic for Plendil®)
nifedipine capsule (generic for Procardia®)	isradipine capsule (generic for Dynacirc®)
nifedipine ER tablet (generic for Adalat CC® / Procardia XL®)	Katerzia® Suspension - T/F of preferred agents not required for children < 12 years of age
Norliva® Solution	levamlodipine tablet (generic for Conjugrip®)
	nicardipine capsule (generic for Cardene®)
	nimodipine capsule (generic for Nimotop®)
	ramodipine solution
	nisoldipine ER tablet (generic for Sular®)
	Norvasc® Tablet
	Nymalize® Solution / oral syringe
	Procardia® XL Tablet
	Sular® Tablet
DIRECT RENIN INHIBITOR	
Preferred	Non-Preferred
Tektura® Tablet	alisikiren tablet (generic for Tektura® Tablet)
ENDOTHELIN RECEPTOR ANTAGONISTS	
Covered for diagnosis of Pulmonary Arterial Hypertension only	
Preferred	Non-Preferred
ambrisentan tablet (generic for Letairis® Tablet)	bosentan tablet /tablet for suspension (generic for Tracleer®)
Tracleer® Tablet	Letairis® Tablet
	Opsumit® Tablet
	Opsumi® Tablet
	Tracleer® Suspension
INHALED PROSTACYCLIN ANALOGS	
Preferred	Non-Preferred
Tyvaso® Refill Kit / Solution / Starter Kit	Tyvaso® DPI
Ventavis® Solution	Yutrepia® DPI
NIACIN DERIVATIVES	
Preferred	Non-Preferred
niacin ER tablet (generic for Niaspan®)	
NITRATE COMBINATION	
Preferred	Non-Preferred
isosorbide dinitr/hydralazine tablet (generic for Bidi®)	Bidi® Tablet
NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS	
Preferred	Non-Preferred
Cartia XT® Capsule (branded generic for Cardizem CD®)	diltiazem LA tablet (generic for Cardizem LA®)
Dilt XR® Capsule (branded generic for Dilacor XR®)	Matzim® LA Tablet (generic for Cardizem LA®)
diltiazem ER 24 hour capsule (generic for Dilacor XR®, Tiazac®)	Verapamil Capsule SR (generic for Verelan®)
diltiazem tablet / CD capsule / ER 12 hour capsule (generic for Cardizem® / CD / SR)	verapamil ER capsule / PM capsule (generic for Verelan® / Verelan® PM)
Taztia XT® Capsule (branded generic for Tiazac®)	Verelan® PM Capsule
Tiadyt® ER Capsule	
verapamil tablet / ER tablet (generic for Calan® / SR)	
ORAL PULMONARY HYPERTENSION	
Covered for diagnosis of Pulmonary Arterial Hypertension (all) and Chronic Thromboembolic Pulmonary Hypertension- Adempas® only	
Preferred	Non-Preferred
Abyq® Tablet (branded generic for tadalafil)	Adcirca® Tablet
sildenafil tablet (generic for Revatio®)	Adempas® Tablet
tadalafil tablet (generic for Adcirca®)	Orenitram® ER Tablet / Titration Kit
	Revatio® Suspension / Tablet - T/F of preferred agents not required for children < 12 years of age for Suspension ONLY
	sildenafil suspension (generic for Revatio®) - T/F of preferred agents not required for children < 12 years of age
	Tadliq® Suspension
	Upitravi® Tablet / Titration Pack
PCSK9	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Clinical criteria apply to all drugs in this class	
Preferred	Non-Preferred
Repatha® Syringe / Pushtronix / Sureclick	Leqvio® Injection
Praluent® Pen	
PLATELET INHIBITORS	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Preferred	Non-Preferred
clopidogrel tablet (generic for Plavix®)	aspirin/dipyridamole ER capsule (generic for Aggrenox®)
dipyridamole tablet (generic for Persantine®)	Brilinta® Tablet
prasugrel tablet (generic for Effient® Tablet)	Effient® Tablet
Ticagrelor Tablet (generic for Brilinta®)	Plavix® Tablet
SYMPATHOLYTICS AND COMBINATIONS	
Preferred	Non-Preferred
clonidine tablet / patch (generic for Catapres® / TTS)	clonidine ER tablet (generic for Nexiclon™ XR)
guanfacine tablet (generic for Tenex®)	Javadin™ Solution
methyl dopa tablet (generic for Aldomet®)	methyl dopa vial (generic for Aldomet®)
	methyl dopa-HCTZ tablet (generic for Aldoni®)
	Nexiclon™ XR Tablet

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill/ FlexPen® / Vial to preferred status in the Hypoglycemics-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (lebrizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED.** For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

MULTIPLE SCLEROSIS		
Injectable		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Avonex® Pack / Pen / Syringe	Briumvi™ Vial	
Betaseron® Kit / Vial	Copaxone® 40 MG/ML Syringe	
Copaxone® Syringe 20 MG/ML	glatiramer syringe 20 MG/ML (generic for Copaxone® Syringe)	
glatiramer syringe 40 MG/ML (generic for Copaxone® Syringe)	Glatopa® Syringe	
Kesimpta® Pen	Lenitrada® Vial	
Rebif® Rebifose® / Titration Pack / Syringe	Ocrevus® Vial - T/F of preferred agents not required for diagnosis of Primary Progressive MS (PPMS)	
	Ocrevus® Zovovo Vial T/F of preferred agents not required for diagnosis of Primary Progressive MS (PPMS)	
	Plegriq® Pen/ Pen Starter Pack / Syringe / Syringe Starter Pack	
	Tysabri® Vial	
Oral		
Preferred		Non-Preferred
dalfampridine ER tablet (generic for Ampyra®)	Ampyra® Tablet	
dimethyl fumarate DR capsule / starter pack (generic for Tecfidera® Capsule / Starter Pack)	Aubagio® Tablet	
fingolimod capsule (generic for Gilenya®)	Bafiertam® Capsule	
teriflunomide tablet (generic for Aubagio®)	Cladribine Tablet (generic for Mavenclad®)	
	Gilenya® Capsule	
	Mavenclad® Tablet	
	Mavzent® Starter Pack / Tablet	
	Ponvory® Starter Pack / Tablet	
	Tascenso ODT™	
	Tecfidera® Capsule / Starter Pack	
	Vumerity™ Capsule	
	Zeposia® Starter Pack / Capsule	
AMYOTROPHIC LATERAL SCLEROSIS (ALS) AGENTS		
Preferred		Non-Preferred
riluzole tablet (generic for Rilutek®)	edaravone infusion bag (generic for Radicava®)	
	edaravone Vial (generic for Radicava®)	
	Qalsody® Vial T/F of preferred agents not required for SOD1 gene mutation	
	Radicava® ORS® Suspension / ORS® Starter Kit Suspension / Infusion Bag	
	Tirolutik® Suspension	
SEDATIVE HYPNOTICS		
Plans may not apply additional utilization management or prior authorization criteria to this category Quantity limits apply to all sedative hypnotics		
Preferred		Non-Preferred
eszopiclone tablet (generic for Lunesta®)	Ambien® Tablet / CR Tablet	
flurazepam capsule (generic for Dalmane®)	Belsonra® Tablet	
ramelteon tablet (generic for Rozerem® Tablet)	Duvygo™ Tablet	
temazepam 15mg, 30mg capsule (generic for Restoril®)	Doral® Tablet	
zaleplon capsule (generic for Sonata®)	doxepin tablet (generic for Silenor®)	
zolpidem tablet (generic for Ambien®)	Edhaur® SL Tablet	
zolpidem ER tablet (generic for Ambien® CR)	estazolam tablet (generic for Prosom®)	
	Halcion® Tablet	
	Hettlioz® Capsule / LQ Suspension - Clinical criteria apply	
	Lunesta® Tablet	
	quazepam tablet (generic for Doral®)	
	Quviviq™ Tablet	
	Restoril® Capsule	
	Rozerem® Tablet	
	tasimelteon capsule (generic for Hettlioz®) - Clinical criteria apply, T/F of Hettlioz® Capsule required for coverage	
	temazepam 7.5, 22.5 mg capsule (generic for Restoril®)	
	triazolam tablet (generic for Halcion®)	
	zolpidem capsule	
	zolpidem SL tablet (generic for Intermezzo®)	
TOBACCO CESSATION		
Preferred		Non-Preferred
bupropion SR tablet (generic for Zyban®)	Nicotrol® Inhaler / NS Nasal Spray	
Chantix® Tablet / Starting Box / Continuation Month Box		
nicotine gum / lozenge (buccal) / patch		
varenicline tablet / starting month box (generic for Chantix®)		
varenicline continuation month box (generic for Chantix®)		
ENDOCRINOLOGY		
GROWTH HORMONE		
Plans may not apply additional utilization management or prior authorization criteria to this category Clinical criteria apply to all drugs in this class		
Prior Approval Not Required for Use of Serostim® in AIDS Wasting Syndrome		
Preferred		Non-Preferred
Genotropin® Cartridge / MiniQuick®	Humatrope® Cartridge	
Norditropin® Flexpro®	Ngenla® Pen	
Skytrofa® Cartridge	Nutropin® AO NuSpin®	
	Omnitrope® Cartridge / Vial	
	Serostim® Vial	
	Sogrova® Pen	
	Zomacton® Vial	
HYPOGLYCEMICS - INJECTABLE		
Rapid Acting Insulin		
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.		
Preferred		Non-Preferred
insulin aspart U-100 Penfill/ FlexPen® / vial (generic for Novolog®)	Admelog® SoloStar® / Vial	
insulin lispro U-100 Junior KwikPen® (generic for Humalog® Junior)	Afrezza® Inhalation Powder	
insulin lispro U-100 KwikPen® / vial (generic for Humalog®)	Apidra® SoloStar® / Vial	
Novolog® U-100 Penfill/ FlexPen® / Vial	Fiasp® FlexTouch® / Penfill® / PumpCart® / Vial	
Relion Novolog® U-100 FlexPen® / Vial	Humalog® U-100 Cartridge/ Junior KwikPen®/ KwikPen® / Vial	
	Humalog® U-100 Tempo Pen™	
	Humalog® U-200 KwikPen®	
	Kirsty Vial / Pen (biosimilar to Novolog®)	
	Lyumjev™ U-100 KwikPen® / U-200 KwikPen® / Vial	
	Merilog Solostar® Pen	
	Merilog™ Vial	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.10.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (elbrikizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

Short Acting Insulin	
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
Preferred	Non-Preferred
Humulin® R Vial	Myxredlin™ Injection
Humulin® R U-500 KwikPen® / U500 Vial	Novolin® R Vial / ReliOn® R Vial
	Novolin R FlexPen® / ReliOn® R FlexPen
Intermediate Acting Insulin	
Preferred	Non-Preferred
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
Humulin® N Vial	Humulin® N KwikPen®
	Novolin® N FlexPen® / ReliOn® N FlexPen®
	Novolin® N Vial / ReliOn® N Vial
Long Acting Insulin	
Plans may not apply additional utilization management or prior authorization criteria to this category	
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
Preferred	Non-Preferred
insulin glargine vial (authorized biologic for Lantus)	Basaglar® U-100 Tempo Pen™
Basaglar® U-100 KwikPen®	insulin degludec pen / vial (generic for Tresiba®)
Lantus® SoloStar® / Vial	insulin glargine SoloStar®/insulin glargine Max SoloStar® (generic for Toujeo®)
	insulin glargine-yfgn pen / vial (generic for Semglee™ yfgn)
	Levemir® / FlexPen® /Vial
	Rezvoglar™ KwikPen®
	Semglee™ yfgn Pen / Vial
	Toujeo® SoloStar® / Max SoloStar®
	Tresiba® FlexTouch® / Vial
Premixed Rapid Combination Insulin	
Preferred	Non-Preferred
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
insulin lispro protamine 75/25 KwikPen® (generic for Humalog® 75/25 Mix)	Humalog® 75/25 Mix KwikPen®
	Humalog® 50/50 Mix KwikPen®
	Humalog® 75/25 Vial
Premixed 70/30 Combination Insulin	
Preferred	Non-Preferred
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
insulin aspart protamine-aspart 70/30 U-100 FlexPen® (generic for Novolog® Mix 70/30)	Novolin® 70/30 FlexPen® / Vial
Humulin® 70/30 KwikPen® / Vial	Novolog® Mix 70/30 Vial / FlexPen®
	Relion Novolin® (human insulin NPH / human insulin) 70/30 FlexPen®
	Relion Novolin® 70/30 Vial
	Relion Novolog® 70/30 Vial / FlexPen®
Amylin Analogs	
Requires T/F or insufficient response to metformin containing product unless contraindicated or documented adverse event when using either a preferred or non-preferred Amylin Analog	
Preferred	Non-Preferred
Symlin® Pen Injector	
GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Clinical criteria apply to all drugs in this class	
Preferred	Non-Preferred
Byetta® Pen	Bydureon® BCise™
Trulicity® Pen	exenatide Pen (generic for Byetta®)
Victoza® Pen	liraglutide pen (generic for Victoza®)
Ozempic® Pen	Mounjaro® Pen
	Rybelsus® Tablet
	Soliqua® Pen
	Xultophy® Pen
HYPOGLYCEMICS - ORAL	
2nd Generation Sulfonylureas	
Preferred	Non-Preferred
glimepiride tablet (generic for Amaril®)	
glipizide tablet / ER tablet (generic for Glucotrol® / XL)	
Glucotrol® XL Tablet	
glyburide micronized tablet (generic for Micromase®, Glynuce®)	
glyburide tablet (generic for Diabeta®)	
Alpha-Glucosidase Inhibitors	
Preferred	Non-Preferred
acarbose tablet (generic for Precose®)	miglitol tablet (generic for Glyset®)
	Precose® Tablet
Biguanides and Combinations	
Preferred	Non-Preferred
glipizide-metformin tablet (generic for Metaglin®)	metformin ER tablet (generic for Fortamet®)
glipizide-metformin tablet (generic for Glucovance®)	metformin ER tablet (generic for Glimepiride®)
metformin tablet / ER tablet (generic for Glucophage® / ER)	metformin solution (generic for Riomet®) - T/F of preferred agents not counted for children < 17 years of age
	metformin tablet (625 mg)
	Riomet® Solution

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Antisialogogues category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® (PanPen®) Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (lebrizumab-ibk) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

DPP-IV Inhibitors and Combinations	
Requires T/F or insufficient response to metformin containing products unless contraindicated or documented adverse event when using either a preferred or a non-preferred DPP-IV Inhibitor or Combination	
Preferred	Non-Preferred
Janumet® Tablet / XR Tablet	alogliptin tablet (generic for Nesima®)
Januvia® Tablet	alogliptin-metformin tablet (generic for Kazano®)
Jentaducto® Tablet / XR Tablet	alogliptin-pioglitazone tablet (generic for Osen®)
Onglyza® Tablet	Brynovin™ Solution
Tradjenta® Tablet	Glycamib® Tablet
	Kazano® Tablet
	Kombiglyze® XR Tablet
	Nesima® Tablet
	Osen® Tablet
	Ottern® Tablet
	saxagliptin tablet (generic for Onglyza®)
	saxagliptin-metformin ER tablet (generic for Kombiglyze® XR)
	sitagliptin / metformin ER Tablet (generic for Zituvinet® XR)
	sitagliptin tablet (generic for Januvia®)
	sitagliptin-metformin tablet (generic for Zituvinet™)
	Steglujan® Tablet
	Trijardy® XR Tablet
	Zituvinet
	Zituvinet XR
	Zituviv™ Tablet
	Meglitinides
Preferred	Non-Preferred
metglinide tablet (generic for Starlix®)	
repaglinide tablet (generic for Prandin®)	
SGLT-2 Inhibitors and Combinations	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Clinical criteria apply to all drugs in this class	
Preferred	Non-Preferred
Farxiga® Tablet	dapagliflozin tablet (generic for Farxiga®)
Jardiance® Tablet	dapagliflozin / metformin ER tablet (generic for Xigduo® XR)
Synjardy® Tablet	Inpefa™ Tablet
Synjardy® XR Tablet	Invokamet® Tablet / XR Tablet
Xigduo® XR Tablet	Invokana® Tablet
	Sezluromet™ Tablet
	Steglato™ Tablet
Thiazolidinediones and Combinations	
Preferred	Non-Preferred
pioglitazone tablet (generic for Actos®)	ActoPlus Met® Tablet
	Actos® Tablet
	Duetact® Tablet
	pioglitazone-glimepiride tablet (generic for Duetact®)
	pioglitazone-metformin tablet (generic for ActoPlus Met®)
GASTROINTESTINAL	
ANTIEMETIC-ANTIVERTIGO AGENTS	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Preferred	Non-Preferred
aprepitant capsule (generic for Emend®) - Clinical criteria apply	Akynzeo® Capsule / Vial
Diclegis® Tablet	Antivert® Tablet / Chewable Tablet
meclizine tablet (generic for Antivert®)	Anzemet® Tablet
metoclopramide solution / tablet (generic for Reglan®)	Aponvie™ Vial
ondansetron ODT 4mg and 8 mg/ solution / tablet (generic for Zofran®)	aprepitant pack (generic for Emend®) - Clinical criteria apply
prochlorperazine tablet (generic for Compazine™)	Barhemsys® Vial
promethazine syrup / suppository (12.5 mg and 25 mg) / tablet / ampule / vial (generic for Phenergan®)	Bojesta® Tablet
Promethegan® (promethazine) Suppository (12.5 mg and 25 mg)	Cinvanti® Vial
scopolamine patch (generic for Transderm-Scop®)	Compro® Suppository
Transderm-Scop® Patch	dimenhydrinate vial (generic for Dramamine®)
	doxylamine-pyridoxine tablet (generic for Diclegis®)
	dromabinol capsule (generic for Marinol®)
	Emend® Capsule / Powder Packet / Trifold Pack - Clinical criteria apply
	Emend® Vial
	Focinvez™ (fosaprepitant) Vial
	fosaprepitant vial (generic for Emend®)
	Gimoti™ Nasal Spray
	granisetron vial / tablet (generic for Kytril®)
	Marinol® Capsule
	metoclopramide vial
	ondansetron ODT (16 mg)
	ondansetron vial
	palonosetron injection (generic for Aloxi®)
	Phenergan® Ampule / Vial
	Posifree™ Ψ Vial
	prochlorperazine vial / suppository (generic for Compazine®)
	Promethegan® Suppository (50 mg)
	Reglan® Tablet
	Sancuso® Patch
	Sustol® Syringe
	Tigan® Vial
	trimethobenzamide capsule (generic for Tigan®)
BILE ACID SALTS	
T/F of only one preferred drug required	
Preferred	Non-Preferred
ursodiol capsule (generic for Actiall®)	Bylvay™ Capsule / Pellet - T/F of preferred agents not required for diagnosis of PFIC
ursodiol tablet (generic for Urso®)	Chenodal® Tablet
	Cholham® Capsule
	Ctexli™ Tablet
	Iqirvo® (clafibranor) Tablet
	Livdelzi Capsule
	Livmarit® Oral Solution/ Tablet
	Ocaliva® Tablet
	Relstone™ Capsule
	Urso Forte® Tablet
H. PYLORI COMBINATIONS	
Preferred	Non-Preferred
Pylera® Capsule	bismuth / metronidazole / tetracycline capsule (generic for Pylera®)
	lanoprazole-amoxicillin-clarithromycin pack (generic for Prevpac®)
	Omeclamox-Pak® Combo Pack
	Talicia® Capsule
	Voquezna® Tablet / Dual Pak / Triple Pak

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.10.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill / Pen to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (elbricitumab-ibk) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

HISTAMINE-2 RECEPTOR ANTAGONISTS		
Preferred		Non-Preferred
famotidine tablet / suspension (generic for Pepcid®)	cimetidine tablet (generic for Tagamet®) cimetidine solution (generic for Tagamet®) nizatidine capsule (generic for Axid®)	
PANCREATIC ENZYMES		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Creon® Capsule Viokase® Tablet Zenpep® Capsule	Pertzye® Capsule	
PROGESTINS USED FOR CACHEXIA		
Preferred		Non-Preferred
megestrol suspension / tablet (generic for Megace®)	megestrol ES suspension (generic for Megace® ES)	
PROTON PUMP INHIBITORS		
Preferred		Non-Preferred
	T/F of preferred agents not required for children < 12 years of age	
esomeprazole magnesium capsule (generic for Nexium® Rx) lansoprazole capsule (generic for Prevacid® Rx) Nexium® Rx Packet omeprazole Rx capsule (generic for Prilosec® Rx) pantoprazole tablet (generic for Protonix®) Protonix® Suspension	Dexilant® Capsule dexlansoprazole capsules (generic for Dexilant®) esomeprazole magnesium OTC capsule / tablet (generic for Nexium® OTC) esomeprazole magnesium packet (generic for Nexium® Rx Packet) Konvomep™ Suspension lansoprazole capsule (generic for Prevacid® OTC) lansoprazole ODT (generic for Prevacid® SoluTab™) Nexium® Rx Capsule omeprazole OTC capsule / ODT / tablet (generic for Prilosec® OTC) omeprazole-sodium bicarbonate capsule / packet (generic for Zegerid® Rx / OTC) pantoprazole suspension (generic for Protonix®) Prevacid® Rx / OTC Capsule / SoluTab Prilosec® Rx Suspension Protonix® Tablet rabeprazole tablet (generic for Aciphex®)	
SELECTIVE CONSTIPATION AGENTS		
Preferred		Non-Preferred
Linzess® Capsule lubiprostone capsule (generic for Amitiza®)	alosetron tablet (generic for Lotronex®) Amitiza® Capsule Ibsrela® Tablet Lotronex® Tablet Motegrity™ Tablet Movantik® Tablet prucalopride tablet (generic for Motegrity®) Symproic® Tablet Viberzi® Tablet - T/F of preferred agents not required for Irritable Bowel Syndrome with Diarrhea (IBS-D)	
ULCERATIVE COLITIS		
Oral		
Preferred		Non-Preferred
balsalazide capsule (generic for Colazal®) Pentasa® Capsule sulfasalazine IR / DR tablet (generic for Azulfidine® / Entab)	Azulfidine® Entab / Tablet budesonide ER tablet (generic for Uceris®) Dipentum® Capsule Lialda® Tablet mesalamine DR capsule / tablet (generic for Delzicol®, Asacol® HD, Lialda®) mesalamine ER capsule (generic for Apriso®, Pentasa®)	
ULCERATIVE COLITIS		
Rectal		
Preferred		Non-Preferred
mesalamine enema (generic for Rowasa®) mesalamine suppository (generic for Canasa®) SF Rowasa® Enema	budesonide rectal foam Canasa® Suppository mesalamine enema (generic for SF Rowasa®) mesalamine kit (generic for Rowasa®) Rowasa® Kit	
GENITOURINARY / RENAL		
ELECTROLYTE DEPLETERS (KIDNEY DISEASE)		
Preferred		Non-Preferred
calcium acetate capsule (generic for PhosLo®) calcium acetate tablet (generic for Eliphos®) sevelamer carbonate powder pack / tablet (generic for Renvela®)	Auryxia® Tablet ferric citrate Tablet (generic for Auryxia®) Fosrenol® Chewable Tablet / Powder Pack lanthanum carbonate chewable tablet (generic for Fosrenol®) MagneBind® 400 Rx Tablet Renvela® Powder Pack / Tablet sevelamer hydrochloride tablet (generic for Renagel®) Velphoro® Chewable Xphozah® Tablet	
BENIGN PROSTATIC HYPERPLASIA TREATMENTS		
Preferred		Non-Preferred
alfuzosin ER tablet (generic for Uroxatral®) doxazosin tablet (generic for Cardura®) dutasteride capsule (generic for Avodart®) finasteride tablet (generic for Proscar®) tamsulosin capsule (generic for Flomax®) terazosin capsule (generic for Hytrin®)	Cardura® Tablet / XL Tablet Cialis® Tablet 5 mg - Clinical criteria apply dutasteride / tamsulosin capsule (generic for Jalyn®) Flomax® Capsule Proscar® Tablet Rapaflo® Capsule silodosin capsule (generic for Rapaflo®) tadalafil tablet (2.5 mg / 5 mg) (generic for Cialis®) - Clinical criteria apply Tenzryl™ Oral Solution	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® (Insulin®) / Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (ibrutinib-mab-ibk) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Vismar® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in RED) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

ANTIBIOTICS	
Preferred	Non-Preferred
bacitracin-polymyxin ointment (generic for Polysporin®)	Azasisite® Drops
ciprofloxacin solution drops (generic for Ciloxan®)	bacitracin ointment (generic for AK-Tracin®)
erythromycin ointment (generic for Ilotycin®)	besifloxacin Suspension (generic for Besivance®)
gentamicin drops (generic for Garamycin®)	Besivance® Suspension
moxifloxacin ophthalmic solution (generic for Vigamox®)	Ciloxan® Ointment
ofloxacin drops (generic for Ocuflox®)	gatifloxacin drops (generic for Zymar®)
Polycin® Ointment (branded generic for Polysporin®)	Levofloxacin Drops (Generic for Levaquin®)
polymyxin-trimethoprim drops (generic for Polyttrim®)	moxifloxacin ophthalmic solution (generic for Moxeza®)
sulfacetamide drops (generic for Bleph-10®)	Natacyn® Drops
tobramycin drops (generic for Tobrex®)	neomycin-bacitracin-polymyxin ointment (generic for Neosporin® Ophthalmic Ointment)
	neomycin-polymyxin-gramicidin drops (generic for Neosporin® Ophthalmic Drops)
	Neo-Polycin® Ointment (branded generic for Neosporin® Ophthalmic Ointment)
	Ocuflox® Drops
	sulfacetamide ointment (generic for Cetamide®)
	Tobrex® Ointment
	Vigamox® Drops
ANTIBIOTICS-STERIOD COMBINATIONS	
Preferred	Non-Preferred
neomycin-polymyxin-dexamethasone drops / ointment (generic for Maxitrol®)	Maxitrol® Drops / Ointment
Tobradex® Ointment	Neo-Polycin® HC (branded generic for Cortisporin®)
tobramycin-dexamethasone suspension (generic for Tobradex®)	neomycin-bacitracin-polymyxin-HC ointment (generic for Cortisporin®)
	neomycin-polymyxin-HC drops (generic for Ocutricin®)
	sulfacetamide-prednisolone drops (generic for Vasocidin®)
	Tobradex® ST Drops
	Zylet® Drops
	loteprednol-tobramycin Drops (generic for Zylet®)
ANTI-INFLAMMATORY	
Preferred	Non-Preferred
dexamethasone drops (generic for Decadron®)	Acular® Drops / LS Solution
diclofenac drops (generic for Voltaren®)	Acuvail® Solution
difluprednate drops (generic for Durezol®)	bromfenac drops (generic for Prolensa®, Xibrom®, BromSite®)
Flarex® Drops	BromSite® Solution
fluorometholone drops (generic for FML®)	Dextenza® Insert
flurbiprofen drops (generic for Ocufen®)	Durezol® Drops
Lotemax® Drops	FML® Forte Drops / Liquifilm® Drops
Nevamc® Droptainer	Ilevro® Drops
Pred Mild® Drops	Iluvien® Implant
prednisolone acetate drops (generic for Pred Forte®)	Invelys™ Drops
	ketorolac solution (generic for Acular® / LS)
	Lotemax® Gel / SM Gel / Ointment
	loteprednol drops / gel (generic for Lotemax®)
	Maxidex® Drops
	Ozurdex® Implant
	Pred Forte® Drops
	prednisolone sodium phosphate drops (generic for Inflammase Forte®)
	Prolensa® Drops
	Retisert® Implant
	Trisence® Vial
	Xipere™ (Intraocular)
	Yutiq® Implant
ANTI-INFLAMMATORY / IMMUNOMODULATOR	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Preferred	Non-Preferred
Restasis® Drops	Cequa™ Drops
Xiidra® Drops	cyclosporine emulsion (generic for Restasis®)
	Eysuvis® Drops
	Miebo™ Drops
	Restasis® Multidose™ Drops
	Tryptyl® Drops
	Tyrvaia® Nasal Spray
	Verkazia® Eye Emulsion - T/F of preferred agents not required for diagnosis of vernal keratoconjunctivitis (VKC)
	Vevvie® Drops
ALPHA 2 ADRENERGIC AGENTS	
Preferred	Non-Preferred
Alphagan® P Drops	apraclonidine drops (generic for Iopidine®)
brimonidine drops (generic for Alphagan®)	brimonidine P drops (generic for Alphagan® P)
	Iopidine® Drops
BETA BLOCKER AGENTS / COMBINATIONS	
Preferred	Non-Preferred
Combigan® Drops	betaxolol drops (generic for Betoptic®)
timolol drops / GFS gel-solution (generic for Timoptic® / Timoptic XE®)	Betimol® Drops
	Betoptic® S Drops
	brimonidine tartrate / timolol drops (generic for Combigan®)
	carteolol drops (generic for Ocupress®)
	Istalol® Drops
	levobunolol drops (generic for Betagan®)
	timolol hemihydrate (generic for Betimol® drops)
	timolol drop (generic for Istalol® Drops)
	timolol maleate drop (generic for Timoptic® Ocudose® Drops)
	Ocudose® Drops
CARBONIC ANHYDRASE INHIBITORS / COMBINATIONS	
Preferred	Non-Preferred
dorzolamide drops (generic for Trusopt®)	Azopt® Drops
dorzolamide-timolol drops (generic for Cosopt®)	brinzolamide drops (generic for Azopt® Drops)
Simbrinza® Drops	Cosopt® Drops / PF Drops
	dorzolamide-timolol PF drops (generic for Cosopt® PF)

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved NovoLog® U-100 PenFill® (InsPen®) / Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (elbrikizumab-ibka) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the **Pharmacy Benefit Administrator** tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

PROSTAGLANDIN AGONISTS		
Preferred		Non-Preferred
latanoprost drops (generic for Xalatan®)		bimatoprost drops (generic for Lumigan® Drops)
Travatan® Z Drops		Durysta® Implant
		iDose® TR Implant
		Iyugeh™ Drops
		Lumigan® Drops
		tafluprost drops (generic for Zioptan®)
		travoprost drops (generic for Travatan® Z)
		Vyzulta® Drops
		Xalatan® Drops
		Xelpros® Drops
		Zioptan® Drops
RHO KINASE MODIFIERS / COMBINATIONS		
Preferred		Non-Preferred
Rhopressa® Drops		
Rocklatan® Drops		
OSTEOPOROSIS		
BONE RESORPTION SUPPRESSION AND RELATED AGENTS		
Preferred		Non-Preferred
alendronate tablet (generic for Fosamax®)		Actonel® Tablet
Bikdyos® Syringe (Prolia® Biosimilar)		alendronate solution (generic for Fosamax® Solution)
Forteo® Pen		Atelvia® Tablet
raloxifene tablet (generic for Evista®)		Binosto® Effervescent Tablet
		Bonsity Pen Injector
		calcitonin salmon nasal spray (generic for Miacalcin®)
		Conexence® Syringe (Prolia® Biosimilar)
		Enoby Syringe (biosimilar to Prolia®)
		Eventy™ Syringe
		Evista® Tablet
		Fosamax® Tablet / Plus D Tablet
		ibandronate tablet (generic for Boniva®)
		Jubbonti® Syringe (Prolia® Biosimilar)
		Ospomyv™ Syringe (Prolia® Biosimilar)
		Prolia® Syringe
		risedronate DR tablet (generic for Atelvia®)
		risedronate tablet (generic for Actonel®)
		Stoboclo® Syringe (Prolia® Biosimilar)
		teriparatide pen (generic for Forteo®)
		Tymlos® Pen
OTIC		
ANTIBIOTICS		
Preferred		Non-Preferred
ciprofloxacin-dexamethasone suspension (generic for Ciprodex®)		Cipro® HC Suspension
neomycin-polymyxin-hydrocortisone solution / suspension (generic for Cortisporin®)		ciprofloxacin solution (generic for Cetraxal®)
ofloxacin drops (generic for Floxin®)		ciprofloxacin-fluocinolone drops (generic for Otovel®)
		Ciprofloxacin-Hydrocortisone Suspension (generic for Cipro® HC)
		Cortisporin-TC® Suspension
		Otovel® Drops
ANTI-INFECTIVES AND ANESTHETICS		
Preferred		Non-Preferred
acetic acid solution (generic for VosoI®)		acetic acid-hydrocortisone solution (generic for VosoI® HC)
ANTI-INFLAMMATORY		
Preferred		Non-Preferred
fluocinolone 0.01% oil (generic for Dermotic®)		Flac® Otic Oil
		Dermotic® Oil
RESPIRATORY		
BETA-ADRENERGIC HANDHELD, LONG ACTING		
Preferred		Non-Preferred
Serevent® Diskus®		Striverdi® Respimat® Inhalation Spray
BETA-ADRENERGIC HANDHELD, SHORT ACTING		
Preferred		Non-Preferred
albuterol HFA inhaler (generic for Proair® HFA Inhaler / Proventil® HFA Inhaler / Ventolin® HFA Inhaler)		levalbuterol HFA inhaler (generic for Xopenex® HFA Inhaler)
Ventolin® HFA Inhaler		Proair® Digihaler™
Xopenex® HFA Inhaler		Proair® RespiClick®
BETA-ADRENERGIC, NEBULIZERS		
T/F of only one preferred drug required		
Preferred		Non-Preferred
albuterol 0.63mg / 3ml solution (generic for Accuneb®)		arformoterol solution (generic for Brovana®)
albuterol 1.25mg / 3ml solution (generic for Accuneb®)		Brovana® Solution
albuterol sulfate 2.5mg / 0.5ml solution		formoterol solution (generic for Perforomist®)
albuterol sulfate 2.5mg / 3ml solution		levalbuterol solution / concentrate solution (generic for Xopenex® / Concentrate)
		Perforomist® Solution
BETA-ADRENERGIC, ORAL		
Preferred		Non-Preferred
albuterol tablets (generic for Proventil® Repetabs)		albuterol ER tablets (generic for VoSpire® ER)
albuterol syrup (generic for Ventolin® Syrup)		
terbutaline tablet (generic for Brethine®)		
ORALLY INHALED ANTICHOLINERGICS / COPD AGENTS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Anoro® Ellipta® Inhaler		Bevespi® Acrosphere®
Atrovent® HFA Inhaler		Daliresp® Tablet
Combivent® Respimat® Inhalation Spray		Duaklir® Pressair®
Incruse® Ellipta® Inhaler		Oltuvayre™ Inhalation suspension
ipratropium nebulizer solution (generic for Atrovent®)		tiotropium inhaler (generic for Spiriva® Handihaler®)
ipratropium / albuterol solution (generic for Duoneb®)		Tudorza® Pressair® Inhaler
roflumilast tablet (generic for Daliresp®)		Umeclidinium-Vilanterol Inhaler (generic for Anoro®)
Spiriva® Handihaler® / Respimat® Inhalation Spray		Yupelri® Solution
Stiolto® Respimat® Inhalation Spray		

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eligius® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® (Insulin) / Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (Ibrikizumab-Ibki) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

INHALED CORTICOSTEROIDS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Alvesco® Inhaler	ArmonAir™ Digihaler™
Armuity® Ellipta® Inhaler	fluticasone furoate DPI (generic for Armuity Ellipta™)
Asmanex® HFA Inhaler / Twisthaler®	fluticasone propionate diskus (generic for Flovent® Diskus)
budesonide suspension 0.25mg, 0.5mg, 1mg (generic for Pulmicort® Respules)	Pulmicort® Respules 0.25mg, 0.5mg, 1mg
fluticasone propionate HFA (generic for Flovent® HFA)	
Pulmicort® Flexhaler	
QVAR® Redihaler™	

INHALED CORTICOSTEROID COMBINATIONS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Advair® Diskus®	AirDuo® Digihaler™ / RespClick®
Advair® HFA Inhaler	AirSupra™ Inhaler
Dulera® Inhaler	Breo® Ellipta®
Symbicort® Inhaler	Breyna™ Inhaler
	Breztri™ Aerosphere™
	budesonide / formoterol inhalation (generic for Symbicort®)
	fluticasone / salmeterol HFA inhaler (generic for Advair® HFA)
	fluticasone / salmeterol inhalation (generic for Advair® Diskus®)
	fluticasone / salmeterol inhalation (generic for AirDuo®)
	fluticasone / vilanterol inhalation (generic for Breo® Ellipta®)
	Trelegy® Ellipta®
	Wixela™ Inhub™

INTRANASAL RHINITIS AGENTS

Preferred	Non-Preferred
	T/F of preferred agents not required in children < 4 years of age for steroid-containing products
azelastine spray (generic for Astelin®)	azelastine nasal spray (generic for Astepro®)
Dymista® Nasal Spray	azelastine-fluticasone nasal spray (generic for Dymista®)
fluticasone spray (generic for Flomase®)	flunisolide nasal spray (generic for Nasalide®)
ipratropium spray (generic for Atrovent® Nasal)	mometasone nasal spray (generic for Nasonex®)
olopatadine nasal spray (generic for Patanase®)	Omnaris® Nasal Spray
	Patanase® Nasal Spray
	QNas® Nasal Spray / Children's Spray
	Ryaltris® Nasal Spray
	Sinuva™ Implant
	Xhance™ Nasal Spray
	Zetonna™ Nasal Spray

LEUKOTRIENE MODIFIERS

Preferred	Non-Preferred
montelukast chewable / tablet (generic for Singulair®)	Accolate® Tablet
	montelukast granules (generic for Singulair®)
	Singulair® Chewable / Granules / Tablet
	zafirlukast tablet (generic for Accolate®)
	zileuton tablet (generic for Zylflo®)
	Zyflo® Filmtab

LOW SEDATING ANTIHISTAMINES

Preferred	Non-Preferred
cetirizine OTC syrup 1mg/1ml (generic for Zyrtec® OTC Syrup)	cetirizine chewable tablet OTC (generic for Zyrtec® OTC Tablet)
cetirizine Rx syrup (generic for Zyrtec® Syrup)	cetirizine OTC syrup 5mg/5ml (generic for Zyrtec® OTC Syrup)
cetirizine tablets OTC (generic for Zyrtec® OTC Tablet)	cetirizine OTC softgel
levocetirizine OTC tablet (generic for Xyzal® OTC Tablet)	Clarinex® Tablet - T/F of preferred agents not required for children < 2 years of age
levocetirizine Rx tablet (generic for Xyzal® Rx Tablet)	desloratadine ODT / Tablet / Solution (generic for Clarinex®) - T/F of preferred agents not required for children < 2 years of age
loratadine tablet OTC (generic for Claritin® OTC)	fexofenadine OTC suspension / OTC tablet (generic for Allegra® OTC)
	levocetirizine Rx solution (generic for Xyzal® Rx Solution)
	loratadine OTC chewable ODT / solution (generic for Claritin® OTC)

LOW SEDATING ANTIHISTAMINE COMBINATIONS

Plans may not apply additional utilization management or prior authorization criteria to this category

Quantity limit of 102 days supply per 12 months apply to all drugs in this class

Preferred	Non-Preferred
loratadine-D OTC tablet (generic for Claritin-D® OTC)	cetirizine-D OTC tablet (generic for Zyrtec-D® OTC)
	Clarinex-D® Tablet
	fexofenadine-D 12 Hour OTC Tablet (generic for Allegra-D® 12 Hour OTC)
	fexofenadine-pseudoephedrine ER 24 hour tablet (generic for Allegra-D® 24 hour)

FIRST GENERATION ANTIHISTAMINES

Preferred	Non-Preferred
carbinoxamine solution	carbinoxamine ER Suspension (generic for Karbinal™) - T/F of immediate release carbinoxamine solution and cetirizine syrup required for coverage
Carbzah Solution	carbinoxamine tablet
cypheptadine syrup / tablet	clemastine tablet (generic for Clemenza™)
hydroxyzine capsule / solution / tablet	Clemenza™ Tablet
	Karbinal™ ER Suspension - T/F of immediate release carbinoxamine solution and cetirizine syrup required for coverage
	RyClora™ Solution
	RyVent™ Tablet
	Vistaryl® Capsule

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Antithrombotics category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® (NovoPen®) Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (elbrikizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

ANTIFUNGALS		
Preferred		Non-Preferred
ciclopirox cream / solution (generic for Loprox [®] , Penlac [™])	Cicloclan [®] Cream / Cream Kit / Kit / Solution	
clotrimazole Rx cream (generic for Lotrimin [®] Rx)	ciclopirox gel / shampoo / suspension (generic for Loprox [®])	
clotrimazole-betamethasone cream (generic for Lotrisone [®])	ciclopirox treatment kit (generic for Cicloclan [®])	
ketoconazole cream / shampoo (generic for Nizoral [®])	clotrimazole Rx solution (generic for Lotrimin [®] Rx)	
Klaryesta [®] Powder (branded generic for Nystop [®])	clotrimazole-betamethasone lotion (generic for Lotrisone [®])	
Nyame [®] Powder (branded generic for Nystop [®])	econazole cream (generic for Spectazole [™])	
nystatin cream / ointment / powder (generic for Mycostatin [®] , Nystop [®])	econazole foam (generic for Ecoza [®])	
Nystop [®] Powder	Ertaczo [®] Cream	
nystatin-triamcinolone cream / ointment (generic for Mycolog II [®])	Extina [®] Foam	
	ketoconazole foam (generic for Extina [®])	
	Ketodan [®] Foam / Foam Kit	
	Loprox [®] Suspension / Cream / Kit	
	luliconazole cream (generic for Lulu [®])	
	micomazole / zinc oxide / petrolatum ointment (generic for Vusion [®]) - Clinical criteria apply	
	naftifine cream / gel (generic for Naftin [®])	
	Naftin [®] Gel	
	oxiconazole cream (generic for Oxistat [®])	
	Oxistat [®] Lotion	
	salicylic acid ointment (generic for Bemsal HP [®])	
	tavaborole topical solution (generic for Kerydin [®])	
	Vusion [®] Ointment - Clinical criteria apply	
ANTIPARASITICS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
	T/F of only one preferred drug required	
Preferred		Non-Preferred
Natroba [®] Topical Suspension	Crotan [™] Lotion	
permethrin cream (generic for Elimite [®])	Elimite [™] Cream	
	Eurax [®] Cream / Lotion	
	malathion lotion (generic for Ovide [®])	
	Ovide [®] Lotion	
	Pruradik [®] Lotion	
	Sklice [®] Lotion	
	spinosad topical suspension (generic for Natroba [®])	
ANTIVIRAL		
Preferred		Non-Preferred
acyclovir Cream / Ointment (generic for Zovirax [®])	penciclovir cream (generic for Denavir [®])	
Denavir [®] Cream		
Imidazoquinolinamines		
Preferred		Non-Preferred
imiquimod cream packet (generic for Aldara [®])	Condylox [®] Gel	
	Hyflor [®] Gel	
	imiquimod cream / cream pump (generic for Zyclara [®])	
	podofilox gel / solution (generic for Condylox [®])	
	Veregen [®] Ointment	
PSORIASIS		
Preferred		Non-Preferred
calcipotriene cream / solution (generic for Dovonex [®])	calcipotriene ointment / foam (generic for Dovonex [®] , Sorilux [®])	
calcipotriene-betamethasone suspension / ointment (generic for Talconex [®])	calcitriol ointment (generic for Vectical [®])	
Vtama [®] Cream	Enstilar [®] Foam	
	Sorilux [®] Foam	
	Taclonex [®] Suspension	
	Vectical Ointment	
	Zoryve [®] 0.3% Cream / Foam	
ROSACEA AGENTS		
Preferred		Non-Preferred
azelaic acid gel (generic for Finacea [®])	brimonidine gel pump (generic for Mirvaso [®])	
Finacea [®] Gel	Epsolay [®] (benzoyl peroxide)	
metronidazole cream (generic for MetroCream [®])	Finacea [®] Foam	
metronidazole gel / pump (generic for MetroGel [®])	ivermectin cream (generic for Soolantra [®])	
Rosadan [®] Cream / Gel	MetroCream [®]	
	MetroGel [®]	
	metronidazole lotion (generic for MetroLotion [®])	
	Mirvaso [®] (brimonidine)	
	Rhofade [®] Cream	
	Rosadan [®] Kit	
	Soolantra [™] Cream	
STEROIDS		
Low Potency		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
desonide cream / ointment (generic for DesOwen [®])	alclometasone dipropionate cream / ointment (generic for Aclovate [®])	
DermaSmoothe [®] FS Scalp and Body Oil	Capex [®]	
hydrocortisone cream / lotion / ointment (generic for Hytone [®])	desonide lotion (generic for DesOwen [®] Lotion)	
	fluocinolone body / scalp oil (generic for DermaSmoothe [®] FS Scalp / Body Oil)	
	Hydrocortisone Solution	
	Hydroxym [®] Gel	
	Texacort [®] Solution	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® (Insulin®) / Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglisys™ (lebrizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED.** For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

ANTIPSORIATICS, ORAL	
Preferred	Non-Preferred
acitretin (generic for Soriatane®)	methoxsalen rapid (generic for Oxsoalen-Ultra®)
EPINEPHRINE, SELF ADMINISTERED	
Plans may not apply additional utilization management or prior authorization criteria to this category Quantity limits apply to all drugs in this class	
Preferred	Non-Preferred
Auvi-Q® Auto Injector	
epinephrine auto injector (generic for Epi-Pen® / Epi-Pen® Jr/ Adrenaclick®)	
Epi-Pen® Auto Injector / 2-Pak / Jr. Auto Injector / Jr. 2-Pak	
neffy® nasal spray	
ESTROGEN AGENTS, COMBINATIONS	
Preferred	Non-Preferred
Activella® Tablet	Abigale™ / Abigale™ Lo Tablet
Amabelz™ Tablet	Bijuva® Capsule
estradiol/norethindrone tablet (generic for Activella®)	
Eyavoh™ Tablet	
Jinteli® (branded generic for FemHRT®)	
Mimvev® / Lo (branded generic for Activella®)	
norethindrone-ethinyl estradiol (generic for FemHRT®)	
Premphase® Tablet	
Prempro® Tablet	
ORAL / TRANSDERMAL ESTROGEN AGENTS AND OTHER	
Preferred	Non-Preferred
Climara® Pro Patch	Climara® Patch
Combipatch® Patch	Conjugated estrogen tablet (generic for Premarin®)
estradiol patch (generic for Climara®, Menostar®, Vivelle-Dot®)	Divigel® Gel Packet
estradiol tablet (generic for Estrace®)	Dotti™ Patch
Evamist® Spray	Duavee® Tablet
Menest® Tablet	Elestrin® Gel
Premarin® Tablet	Estrace® Tablet
	estradiol gel packet (generic for Divigel®)
	Estradiol Gel Pump
	Lyllana™ Patch
	Lynkuet® Capsule
	Menostar® Patch
	Minivelle® Patch
	Osphena® Tablet
	Veozah™ Tablet
	Vivelle-Dot® Patch
ESTROGEN AGENTS, VAGINAL PREPARATIONS	
Preferred	Non-Preferred
estradiol vaginal cream (generic for Estrace®)	Estrace® Cream
Estring® Vaginal Ring	estradiol tablet (generic for Vagifem®)
Premarin® Vaginal Cream	Femring® Vaginal Ring
Vagifem® Vaginal Tablet	Imvexxy® Vaginal Inserts
	Yuvafem® Vaginal Tablet
GLUCOCORTICOID STEROIDS, ORAL	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Preferred	Non-Preferred
budesonide EC capsule (generic for Entocort® EC)	Alkindi® Sprinkle Capsule
dexamethasone elixir / tablet (generic for Decadron®)	Agamree® Suspension
dexamethasone solution (generic for Concedex®)	Cortel® Tablet
Emflaza® Tablet / Suspension - Clinical criteria apply	cortisone tablet (generic for Patison®)
hydrocortisone tablet	deflazacort suspension (generic for Emflaza®) - Clinical criteria apply.
methylprednisolone 4mg dosepack / tablet (generic for Medrol®)	deflazacort tablet (generic for Emflaza®) - Clinical criteria apply
prednisolone sodium phosphate solution (generic for PediaPred®, OraPred®, Veripred®)	dexamethasone tablet dosepack / Intensol® Drops
prednisolone solution (generic for Prelone®, Millipred®)	Eohila® Suspension- T/F of preferred agents not required for diagnosis of eosinophilic esophagitis
prednisone dose pack (generic for Sterapred®)	Hemady® Tablet
prednisone solution / tablet (generic for Deltasone®)	Jaythari Tablet / Suspension (generic for Emflaza®) - Clinical criteria apply
	Khindivi™ Solution
	Kymbee™ Tablet
	Medrol® Dose Pack / Tablet
	methylprednisolone 8mg / 16mg / 32mg tablet (generic for Medrol®)
	Millipred® Dose Pack / Tablet
	prednisolone ODT (generic for Orapred® ODT)
	prednisolone tablet
	Prednisone Intensol® Concentrated Solution
	Prednisone Tablet DR (generic for Rayvos®)
	Pyquini™ Suspension (generic for Emflaza®) - Clinical criteria apply
	Rayvos® Tablet
	Taperdex® Tablet
	Tarpeyo™ Capsule - T/F of preferred agents not required for diagnosis of IgA nephropathy

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Antisecretorys category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill / PenPod® Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026.
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss™ (elbricitumab-ibk) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen™ to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in RED) may also apply. New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/program-services/prescription-drugs/outpatient-pharmacy-services>

HEREDITARY ANGIOEDEMA (HAE) PROPHYLAXIS AGENTS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all drugs in this class		
Preferred		Non-Preferred
Haegarda® Vial	Cinryze® Vial	
Orladeyo® Capsule	Dawnezera™ Auto syringe	
	Takhtzyro® Vial / Syringe	
HEREDITARY ANGIOEDEMA (HAE) TREATMENT AGENTS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all drugs in this class		
Preferred		Non-Preferred
Beriner® Vial / Kit	Ekterly® Tablet	
icatibant syringe (generic for Firazyr®)	Andenbry® Auto Injector	
Kalbitor® Vial	Firazyr® Syringe	
Sajazir™ Syringe (branded generic for icatibant)	Ruconest® Vial	
OPIOID ANTAGONISTS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Kloxxado™ Nasal Spray		
LifEMS™ naloxone Syringe Kit		
naloxone nasal spray (OTC)		
naloxone syringe / spray / vial (generic for Narcan®)		
naltrexone tablet		
Narcan® Nasal Spray (OTC)		
Opvee® Nasal Spray		
Rextovy™ (naloxone) Nasal Spray		
Vivitrol® Vial / Diluent		
Zimhi™ Syringe		
Zurnai® Injection		
OPIOID DEPENDENCE		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Prior Approval Not Required for Coverage of Preferred Agents		
Clinical Criteria Apply to Non-Preferred Agents		
Brixadi™ Weekly Syringe / Monthly Syringe	buprenorphine-naloxone SL film (generic for Suboxone®)	
buprenorphine-naloxone SL tablet (generic for Suboxone®)	Lofexidine Tablet T/F of preferred agents not required for diagnosis of opioid withdrawal	
buprenorphine SL tablet (generic for Subutex®)	Lucemyra® Tablet - T/F of preferred agents not required for diagnosis of opioid withdrawal	
Suboxone® SL Film	Zubsolv® Tablet SL	
Sublocade® Syringe		
SKELETAL MUSCLE RELAXANTS		
Preferred		Non-Preferred
baclofen tablet (generic for Lioresal®)	Amrix® ER Capsule	
cyclobenzaprine tablet (generic for Flexeri®)	baclofen oral solution	
methocarbamol tablet (generic for Robaxin®)	baclofen suspension (generic for Flecuvay™)	
tizanidine tablet (generic for Zanaflex®)	chlorzoxazone tablet (generic for Parafon Forte®)	
	cyclobenzaprine ER capsule (generic for Amrix® ER)	
	Dantrium® Capsule / Vial	
	dantrolene sodium capsule (generic for Dantrium®)	
	Fexmid® Tablet	
	Flecuvay™ Suspension	
	Lorzone® Tablet	
	Lyvispah® Granule Packet	
	metaxalone tablet (generic for Skelaxin®)	
	Norgesic™ Tablet / Forte Tablet	
	orphenadrine / aspirin / caffeine tablet (generic for Norgesic™)	
	orphenadrine citrate tablet / vial (generic for Norflex®)	
	Orphenesic® Forte Tablet	
	Ozobax DS® Solution	
	Ozobax® Solution	
	Robaxin® Vial	
	Tanlor® Tablet	
	tizanidine capsules (generic for Zanaflex®)	
	Tommya™ Sublingual Tablet	
	Zanaflex® Capsule / Tablet	
DISPOSABLE INSULIN DELIVERY DEVICES		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
CoQur Simplicity™		
CoQur Simplicity™ Inserter		
ilet Infusion Kit		
ilet Starter Kit		
Omnipod 5® DexG7/G6 Intro Kit/Pods (GEN5), FSL2 G6 Intro Kit/Pods		
Omnipod DASH® Pods (5-Pack) / Intro Kit		
Omnipod GO™ Pods		
DIABETIC CONTINUOUS GLUCOSE MONITOR SUPPLIES		
Continuous Glucose Monitor Transmitters / Receivers / Readers		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all items in this class		
Preferred		Non-Preferred
Dexcom G6® Transmitter / Receiver	Freestyle Libre™ 14 day Reader	
Dexcom G7® Receiver		
Freestyle Libre™ 2 Reader		
Freestyle Libre™ 3 Reader		
Continuous Glucose Monitor Sensors		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all items in this class		
Preferred		Non-Preferred
Freestyle Libre™ 2 Sensor	Freestyle Libre™ 14 day Sensor	
Freestyle Libre™ 2 Plus Sensor		
Freestyle Libre™ 3 Sensor		
Freestyle Libre™ 3 Plus Sensor		
Dexcom G6® Sensor		
Dexcom G7® Sensor (10 day sensor and 15 day sensor)		

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date July 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.
Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® / Vial to preferred status in the Hypoglycemic-Injectables: Rapid acting Insulin category, due to patient access, effective 03.20.2026
Revised 03.31.2026 Off-Cycle Change: Moved Ebglyss® (lebrkizamab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; and moved Viamra® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.
Revised 07.24.2026 Off-Cycle Change: Moved Basaglar® U-100 KwikPen® to preferred in the Insulin Long Acting category effective 07.24.2026

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated..

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to
T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at:

<https://mes.medicaid.ncdhhs.gov/> then click on the Pharmacy Benefit Administrator tile.

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

DIABETIC SUPPLIES

Plans may not apply additional utilization management or prior authorization criteria to this category

N.C. Medicaid only covers, at point of sale, the designated preferred products listed below for blood glucose meters, diabetic test strips, control solutions, lancets, and lancing devices for Medicaid-primary recipients (dually eligible and third-party recipients are not affected). These products are covered under the Outpatient Pharmacy Program and can be submitted to the pharmacy point-of-sale system with a prescription. Diabetic supplies, including other brands, can also be submitted under Durable Medical Equipment using the NDC and HCPCS code. Beneficiaries are allowed 1 covered meter every 2 years (730 days). For questions or assistance regarding diabetic supplies for Medicaid Direct members, please call the Prime Therapeutics call center at 1-844-620-6116. *All blood glucose meters are billed using the NC Medicaid Free BIN Meter program. BIN 610524, PCN 1016, Group 40026479, ID 06649643.

Meters	Lancing Devices
ACCU-CHEK® Guide Retail care kit * (see above for billing)	ACCU-CHEK® Softclix lancing device kit (Black)
ACCU-CHEK® Guide Me Retail care kit * (see above for billing)	ACCU-CHEK® Fastclix lancing device kit
Test Strips	Control Solutions
ACCU-CHEK® AVIVA PLUS 50 ct test strips	ACCU-CHEK® Aviva glucose control solution (2 levels)
ACCU-CHEK® SMARTVIEW 50 ct test strips	ACCU-CHEK® SmartView glucose control solution (1 level)
ACCU-CHEK® Guide 50 ct test strips	ACCU-CHEK® Guide 2-Level control solution (2-levels)
ACCU-CHEK® Guide 100 ct test strips	
Lancets	
ACCU-CHEK® Softclix 100 ct Lancets	
ACCU-CHEK® Fastclix 102 ct Lancets	